BackgroundCannabis use has increased across Europe over the last decade, accompanied by growing availability of high-potency THC products and rising psychiatric presentations. Despite these trends, European countries differ substantially in monitoring systems, clinical preparedness and public health responses. These disparities are especially visible between Western Europe, which has more developed pharmacovigilance systems, diagnostic networks, and addiction psychiatry services, and other regio